This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gulley, M. L. Search for Related Content PubMed PubMed Citation Articles by Gulley, M. L.

JMD 2001, Vol. 3, No. 1
Copyright © 2001 American Society for Investigative Pathology & Association for Molecular Pathology

Review

Molecular Diagnosis of Epstein-Barr Virus-Related Diseases

From the Department of Pathology, University of Texas Health Science Center at San Antonio and the Audie L. Murphy Memorial Veteran’s Hospital, San Antonio, Texas

Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis, and it may also be found in a wide variety of benign and malignant lesions including oral hairy leukoplakia, inflammatory pseudotumor, Hodgkin’s disease, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. Molecular testing is increasingly important in the diagnosis and monitoring of patients affected by these diseases. In biopsy tissues, molecular detection of EBV-encoded RNA transcripts by in situ hybridization remains the gold standard for proving that a histopathological lesion is EBV-related. EBV-encoded RNA hybridization and EBV LMP1 immunostains are used routinely to detect latent EBV in tissues affected by posttransplant lymphoproliferative disorder (PTLD) or in enlarged nodes from patients with infectious mononucleosis. Traditional serology is the best test for evaluating acute versus remote infection in healthy individuals. High serological titers serve as a tumor marker for some EBV-related malignancies, but titers are not a dependable tumor marker in immunocompromised hosts. EBV viral load testing by quantitative DNA amplification of blood samples is a promising new laboratory test that has proven useful for early diagnosis and monitoring patients with PTLD. Recent studies suggest a role for EBV viral load testing in nasopharyngeal carcinoma, Hodgkin’s disease, and AIDS patients with brain lymphoma. Further research is needed to define more fully the clinical utility of viral load tests in the full spectrum of EBV-associated diseases. Gene expression profiling is on the horizon as a means to improve subclassification of EBV-related diseases and to predict response to therapy.

This article has been cited by other articles:

				A.-D. Gu, Y.-B. Xie, H.-Y. Mo, W.-H. Jia, M.-Y. Li, M. Li, L.-Z. Chen, Q.-S. Feng, Q. Liu, C.-N. Qian, et al. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology J. Gen. Virol., May 1, 2008; 89(5): 1152 - 1158. [Abstract] [Full Text] [PDF]

				M. L. Gulley, H. Fan, and S. H. Elmore Validation of Roche LightCycler Epstein-Barr Virus Quantification Reagents in a Clinical Laboratory Setting J. Mol. Diagn., November 1, 2006; 8(5): 589 - 597. [Abstract] [Full Text] [PDF]

				M. J. Espy, J. R. Uhl, L. M. Sloan, S. P. Buckwalter, M. F. Jones, E. A. Vetter, J. D. C. Yao, N. L. Wengenack, J. E. Rosenblatt, F. R. Cockerill III, et al. Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing Clin. Microbiol. Rev., January 1, 2006; 19(1): 165 - 256. [Abstract] [Full Text] [PDF]

				S. J. C. Stevens, S. A. W. M. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia J. Clin. Microbiol., July 1, 2005; 43(7): 3066 - 3073. [Abstract] [Full Text] [PDF]

				G. Ruiz, P. Pena, F. de Ory, and J. E. Echevarria Comparison of Commercial Real-Time PCR Assays for Quantification of Epstein-Barr Virus DNA J. Clin. Microbiol., May 1, 2005; 43(5): 2053 - 2057. [Abstract] [Full Text] [PDF]

				J. L. Ryan, H. Fan, S. L. Glaser, S. A. Schichman, N. Raab-Traub, and M. L. Gulley Epstein-Barr Virus Quantitation by Real-Time PCR Targeting Multiple Gene Segments: A Novel Approach to Screen for the Virus in Paraffin-Embedded Tissue and Plasma J. Mol. Diagn., November 1, 2004; 6(4): 378 - 385. [Abstract] [Full Text] [PDF]

				R. Germi, P. Morand, K. Brengel-Pesce, S. Fafi-Kremer, O. Genoulaz, C. Ginevra, M. Ballout, G. Bargues, and J.-M. Seigneurin Quantification of gp350/220 Epstein-Barr Virus (EBV) mRNA by Real-Time Reverse Transcription-PCR in EBV-Associated Diseases Clin. Chem., October 1, 2004; 50(10): 1814 - 1817. [Full Text] [PDF]

				S. L. Glaser, J. L. Hsu, and M. L. Gulley Epstein-Barr Virus and Breast Cancer: State of the Evidence for Viral Carcinogenesis Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 688 - 697. [Abstract] [Full Text] [PDF]

				M. P. Thompson and R. Kurzrock Epstein-Barr Virus and Cancer Clin. Cancer Res., February 1, 2004; 10(3): 803 - 821. [Abstract] [Full Text] [PDF]